Alzinova AB (ALZ) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.113x

Based on the latest financial reports, Alzinova AB (ALZ) has a cash flow conversion efficiency ratio of -0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-16.80 Million ≈ $-1.81 Million USD) by net assets (Skr148.71 Million ≈ $16.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Alzinova AB stock valuation for the company's overall valuation and market capitalisation.

Alzinova AB - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Alzinova AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Alzinova AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Alzinova AB ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Alzinova AB to evaluate how effectively operating cash flow covers total debt obligations.

Company Cash Flow Conversion Efficiency
LBI Capital Bhd
KLSE:8494
-0.200x
Moonpig Group PLC
LSE:MOON
-0.276x
Palamina Corp
V:PA
-1.095x
Wise Group AB
ST:WISE
0.075x
Green Packet Bhd
KLSE:0082
0.221x
Reliance Chemotex Industries Limited
NSE:RELCHEMQ
0.161x
Nexted Group Ltd
AU:NXD
0.510x
TFP Solutions Bhd
KLSE:0145
-0.142x

Annual Cash Flow Conversion Efficiency for Alzinova AB (2014–2025)

The table below shows the annual cash flow conversion efficiency of Alzinova AB from 2014 to 2025. View ALZ stock price and chart for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr121.96 Million
≈ $13.12 Million
Skr-13.03 Million
≈ $-1.40 Million
-0.107x +34.72%
2024-12-31 Skr123.82 Million
≈ $13.33 Million
Skr-20.27 Million
≈ $-2.18 Million
-0.164x -22.49%
2023-12-31 Skr113.86 Million
≈ $12.25 Million
Skr-15.21 Million
≈ $-1.64 Million
-0.134x -36.72%
2022-12-31 Skr105.53 Million
≈ $11.36 Million
Skr-10.31 Million
≈ $-1.11 Million
-0.098x +11.95%
2021-12-31 Skr88.47 Million
≈ $9.52 Million
Skr-9.82 Million
≈ $-1.06 Million
-0.111x -70.10%
2020-12-31 Skr96.02 Million
≈ $10.33 Million
Skr-6.27 Million
≈ $-674.29K
-0.065x +2.98%
2019-12-31 Skr59.11 Million
≈ $6.36 Million
Skr-3.98 Million
≈ $-427.85K
-0.067x -8.08%
2018-12-31 Skr63.75 Million
≈ $6.86 Million
Skr-3.97 Million
≈ $-426.95K
-0.062x +14.16%
2017-12-31 Skr29.39 Million
≈ $3.16 Million
Skr-2.13 Million
≈ $-229.31K
-0.072x +16.33%
2016-12-31 Skr31.90 Million
≈ $3.43 Million
Skr-2.76 Million
≈ $-297.46K
-0.087x +44.29%
2015-12-31 Skr20.63 Million
≈ $2.22 Million
Skr-3.21 Million
≈ $-345.40K
-0.156x +66.23%
2014-12-31 Skr1.55 Million
≈ $167.09K
Skr-715.19K
≈ $-76.97K
-0.461x --

About Alzinova AB

ST:ALZ Sweden Biotechnology
Market Cap
$9.77 Million
Skr90.78 Million SEK
Market Cap Rank
#27219 Global
#589 in Sweden
Share Price
Skr0.45
Change (1 day)
+7.31%
52-Week Range
Skr0.40 - Skr2.03
All Time High
Skr26.90
About

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide … Read more